Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Income from Continuing Operations (2016 - 2025)

Rocket Pharmaceuticals' Income from Continuing Operations history spans 10 years, with the latest figure at 43746000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 28.93% year-over-year to 43746000.0; the TTM value through Dec 2025 reached 230420000.0, up 13.64%, while the annual FY2025 figure was 230420000.0, 13.64% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 43746000.0 at Rocket Pharmaceuticals, up from 52011000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 33798000.0 in Q2 2021 and bottomed at 71889000.0 in Q2 2024.
  • The 5-year median for Income from Continuing Operations is 61152000.0 (2023), against an average of 57148050.0.
  • The largest annual shift saw Income from Continuing Operations crashed 71.22% in 2021 before it increased 28.93% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 43945000.0 in 2021, then tumbled by 55.43% to 68304000.0 in 2022, then rose by 7.86% to 62935000.0 in 2023, then rose by 2.2% to 61550000.0 in 2024, then rose by 28.93% to 43746000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Income from Continuing Operations are 43746000.0 (Q4 2025), 52011000.0 (Q3 2025), and 71139000.0 (Q2 2025).